Get Well Soon, Molly
Fans of Molly Ivins have probably noticed that her work has been absent from this page and others in recent weeks. Unfortunately, Molly's battle with cancer has forced her to take a break from her crusade against the war. Our thoughts and hearts are with her at this difficult time.
Fans of Molly Ivins have probably noticed that her work has been absent from this page and others in recent weeks. Unfortunately, Molly’s battle with cancer has forced her to take a break from her crusade against the war. Our thoughts and hearts are with her at this difficult time.
If you need a fix, you can read some of Molly Ivins’ indomitable wit here.
Click here for more on Molly’s condition.
Your support is crucial…With an uncertain future and a new administration casting doubt on press freedoms, the danger is clear: The truth is at risk.
Now is the time to give. Your tax-deductible support allows us to dig deeper, delivering fearless investigative reporting and analysis that exposes what’s really happening — without compromise.
Stand with our courageous journalists. Donate today to protect a free press, uphold democracy and unearth untold stories.
Film
Cinema’s most striking colorist paints a scene from the end of life.
Environment
Though it causes more cancer than any other toxic air pollutant, little is being done to curb the risk posed by the ubiquitous gas.
Ear to the Ground
After promising to remove glyphosate from its popular herbicide, Bayer has instead made its lawn products vastly more toxic.
Health & Wellness
As medical assistance in dying becomes legal in Vermont and Oregon, terminally ill patients find themselves traveling to die on their terms.
Military
While the U.S. military used the herbicide to defoliate the jungles of Southeast Asia, it sprayed the same chemicals to kill poison oak and other weeds in northern California.
Global Voices
When “forever chemicals” contaminated their water, Italian mothers got organized and took the polluters to court.
You need to be a supporter to comment.
There are currently no responses to this article.
Be the first to respond.